Answers are grounded in this paper and cite their sources.
Background/Objectives: Lower-cost biosimilar semaglutide products are increasingly used in settings where the innovator product is unaffordable, yet long-term comparative clinical data from the populations that use them are scarce. We compared the 52-week effectiveness, persistence and safety of biosimilar and innovator semaglutide in adults with type 2 diabetes. Methods: We emulated a target equivalence trial using routinely collected records of 1000 adults (18–75 years; HbA1c 7.0–10.0%) who initiated once-weekly biosimilar (n = 500) or innovator (n = 500) semaglutide at two specialist diabetes centres in Islamabad, Pakistan, between December 2024 and July 2025, with follow-up to July 2026. Confounding was addressed by propensity score overlap weighting on 14 baseline covariates. The primary outcome, change in HbA1c from baseline to week 52 among all initiators, was estimated by overlap-weighted analysis of covariance after multiple imputation; equivalence required the 90% confidence interval (CI) to lie within ±0.30 percentage points. Results: Overlap weighting achieved exact covariate balance, with an effective sample size of 976. HbA1c decreased by 1.42 and 1.39 percentage points with biosimilar and innovator semaglutide, respectively (adjusted difference −0.03; 90% CI −0.12 to 0.07), meeting the equivalence criterion; all eight sensitivity analyses concurred. Body weight decreased by 6.3% and 6.2% (difference −0.13%; 95% CI −0.71 to 0.45), and none of 27 secondary cardiometabolic outcomes differed after false-discovery-rate control. Persistence at 52 weeks was 93.2% and 94.6% (hazard ratio for discontinuation 1.29; 95% CI 0.77–2.14), and recorded adverse events were comparable. Conclusions: In routine practice, biosimilar semaglutide was equivalent to innovator semaglutide in HbA1c reduction over 52 weeks, with comparable weight, cardiometabolic, persistence and safety outcomes. Prospective multicentre studies including immunogenicity assessment are warranted.
No takes yet. Share an insight, caveat, or question.
Niaz et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: